|Treatments:||Radiation, Biologic therapy||Hospital:||Centre Hospitalier de l'Université de Montréal|
This study involved 93 indolent non-Hodgkin lymphoma patients who had received prior rituximab-based biologic therapy. The median patient age was 59 years and 53.8% were male.
Patients received biologic therapy with tositumomab (a monoclonal antibody that binds to the CD20 protein on the surface of lymphoma cells) and radiation therapy with I131-tositumomab (radiation-labeled form of tositumomab).
Treatment-related deaths due to infection, respiratory failure, and myelodysplastic syndrome (MDS) were reported, as was grade 3-4 fatigue, shortness of breath, and pain.
The median overall survival was 59.8 months.
This study was funded by GlaxoSmithKline, Inc.
Correspondence: Dr. Harold J. Olney; email: email@example.com